Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well...
Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well tolerated when used in conjunction with Roche's Avastin in a Phase II trial, with no additional safety concerns. Oxigene expects patient accrual for the study to be completed within the next 3-4 months and for top-line data to be available at the end of the year. (PR)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs